Key points from article :
Novartis has entered a partnership with Generate:Biomedicines to leverage artificial intelligence (AI) for discovering and developing protein-based therapeutics across multiple disease areas. The collaboration, valued at over $1 billion, aims to speed up drug discovery while reducing costs by combining Generate’s AI-driven "generative biology" platform with Novartis’ expertise in clinical development and biologics.
Generate’s technology uses machine learning to analyse vast protein datasets and design new therapeutic proteins, potentially shaving two years off traditional drug development timelines. The partnership will focus on creating first-in-class and best-in-class molecules, though specific disease targets remain undisclosed. Novartis has agreed to pay Generate $65 million upfront, with additional milestone payments and royalties.
This collaboration is part of Novartis’ broader AI-driven strategy in drug discovery, complementing its existing partnerships with Microsoft and other biotech firms. Generate, backed by investors like Flagship Pioneering and NVIDIA’s venture arm, has raised nearly $700 million in equity funding and is emerging as a key player in AI-powered drug development.
